Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering ...

DURHAM, NC — Projected lifetime treatment with the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) appears to be cost-effective vs warfarin for patients with atrial fibrillation, ...

Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...

The factor Xa inhibitor apixaban is noninferior to conventional therapy with enoxaparin and a vitamin K antagonist in patients with acute venous thromboembolism (VTE). The study, published online July ...

At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...

Please provide your email address to receive an email when new articles are posted on . Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Treatment with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), regardless of dosage, was associated with significantly less major bleeding compared with warfarin in a particularly high-risk ...

Formulary restrictions can create treatment barriers for patients with atrial fibrillation, including unnecessary delays in treatment and prescription abandonment, with vulnerable populations at ...

Results of a study comparing apixaban with low-molecular-weight heparin as a treatment to prevent recurrent blood clots in patients with cancer may assuage some of the concern about the bleeding risk ...

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, ...